339 related articles for article (PubMed ID: 26071821)
1. Outcomes with Angiotensin-converting Enzyme Inhibitors vs Other Antihypertensive Agents in Hypertensive Blacks.
Bangalore S; Ogedegbe G; Gyamfi J; Guo Y; Roy J; Goldfeld K; Torgersen C; Capponi L; Phillips C; Shah NR
Am J Med; 2015 Nov; 128(11):1195-203. PubMed ID: 26071821
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis.
Suchard MA; Schuemie MJ; Krumholz HM; You SC; Chen R; Pratt N; Reich CG; Duke J; Madigan D; Hripcsak G; Ryan PB
Lancet; 2019 Nov; 394(10211):1816-1826. PubMed ID: 31668726
[TBL] [Abstract][Full Text] [Related]
3. Add-On Antihypertensive Medications to Angiotensin-Aldosterone System Blockers in Diabetes: A Comparative Effectiveness Study.
Schroeder EB; Chonchol M; Shetterly SM; Powers JD; Adams JL; Schmittdiel JA; Nichols GA; O'Connor PJ; Steiner JF
Clin J Am Soc Nephrol; 2018 May; 13(5):727-734. PubMed ID: 29572286
[TBL] [Abstract][Full Text] [Related]
4. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Wright JT; Dunn JK; Cutler JA; Davis BR; Cushman WC; Ford CE; Haywood LJ; Leenen FH; Margolis KL; Papademetriou V; Probstfield JL; Whelton PK; Habib GB;
JAMA; 2005 Apr; 293(13):1595-608. PubMed ID: 15811979
[TBL] [Abstract][Full Text] [Related]
5. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
[TBL] [Abstract][Full Text] [Related]
6. Renin-Angiotensin System Inhibitors vs Other Antihypertensives in Hypertensive Blacks: A Meta-Analysis.
Palla M; Ando T; Androulakis E; Telila T; Briasoulis A
J Clin Hypertens (Greenwich); 2017 Apr; 19(4):344-350. PubMed ID: 27378313
[TBL] [Abstract][Full Text] [Related]
7. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763
[TBL] [Abstract][Full Text] [Related]
8. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
[TBL] [Abstract][Full Text] [Related]
9. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Leenen FH; Nwachuku CE; Black HR; Cushman WC; Davis BR; Simpson LM; Alderman MH; Atlas SA; Basile JN; Cuyjet AB; Dart R; Felicetta JV; Grimm RH; Haywood LJ; Jafri SZ; Proschan MA; Thadani U; Whelton PK; Wright JT;
Hypertension; 2006 Sep; 48(3):374-84. PubMed ID: 16864749
[TBL] [Abstract][Full Text] [Related]
10. Use of Antihypertensive Agents and Association With Risk of Adverse Outcomes in Chronic Kidney Disease: Focus on Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers.
Ku E; McCulloch CE; Vittinghoff E; Lin F; Johansen KL
J Am Heart Assoc; 2018 Oct; 7(19):e009992. PubMed ID: 30371331
[TBL] [Abstract][Full Text] [Related]
11. Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.
Lynch AI; Boerwinkle E; Davis BR; Ford CE; Eckfeldt JH; Leiendecker-Foster C; Arnett DK
Pharmacogenet Genomics; 2009 Jun; 19(6):415-21. PubMed ID: 19352213
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitor-Based Treatment on Cardiovascular Outcomes in Hypertensive Blacks Versus Whites.
Ogedegbe G; Shah NR; Phillips C; Goldfeld K; Roy J; Guo Y; Gyamfi J; Torgersen C; Capponi L; Bangalore S
J Am Coll Cardiol; 2015 Sep; 66(11):1224-1233. PubMed ID: 26361152
[TBL] [Abstract][Full Text] [Related]
13. Association between cardiovascular outcomes and antihypertensive drug treatment in older women.
Wassertheil-Smoller S; Psaty B; Greenland P; Oberman A; Kotchen T; Mouton C; Black H; Aragaki A; Trevisan M
JAMA; 2004 Dec; 292(23):2849-59. PubMed ID: 15598916
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Cardiovascular Events Among Users of Different Classes of Antihypertension Medications: A Systematic Review and Network Meta-analysis.
Wei J; Galaviz KI; Kowalski AJ; Magee MJ; Haw JS; Narayan KMV; Ali MK
JAMA Netw Open; 2020 Feb; 3(2):e1921618. PubMed ID: 32083689
[TBL] [Abstract][Full Text] [Related]
15. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.
Black HR; Elliott WJ; Grandits G; Grambsch P; Lucente T; White WB; Neaton JD; Grimm RH; Hansson L; Lacourciere Y; Muller J; Sleight P; Weber MA; Williams G; Wittes J; Zanchetti A; Anders RJ;
JAMA; 2003 Apr 23-30; 289(16):2073-82. PubMed ID: 12709465
[TBL] [Abstract][Full Text] [Related]
16. Antihypertensive drug therapies and the risk of ischemic stroke.
Klungel OH; Heckbert SR; Longstreth WT; Furberg CD; Kaplan RC; Smith NL; Lemaitre RN; Leufkens HG; de Boer A; Psaty BM
Arch Intern Med; 2001 Jan; 161(1):37-43. PubMed ID: 11146696
[TBL] [Abstract][Full Text] [Related]
17. Managing hypertension using combination therapy.
Frank J
Am Fam Physician; 2008 May; 77(9):1279-86. PubMed ID: 18540493
[TBL] [Abstract][Full Text] [Related]
18. Diuretic or Beta-Blocker for Hypertensive Patients Already Receiving ACEI/ARB and Calcium Channel Blocker.
Tsai MS; Tang CH; Lin CY; Chuang PY; Chen NC; Huang CH; Chang WT; Wang TD; Yu PH; Chen WJ
Cardiovasc Drugs Ther; 2017 Dec; 31(5-6):535-543. PubMed ID: 29218625
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: Systematic review and meta-analysis.
Salvador GL; Marmentini VM; Cosmo WR; Junior EL
Eur J Prev Cardiol; 2017 Dec; 24(18):1914-1924. PubMed ID: 28862020
[TBL] [Abstract][Full Text] [Related]
20. Diuretics versus others for long-term clinical outcomes as first-line antihypertensive medications: analysis of national real-world database.
Kim HL; Hwang D; Lee JH; Lee HY; Ihm SH; Kim KI; Shin J; Park S; Kim DH; Sung KC
Hypertens Res; 2022 May; 45(5):758-768. PubMed ID: 35338336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
